Overview Dividends

(KVUE) Kenvue - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US49177J1025

Pain Relief, Allergy Relief, Skincare, Haircare, Oral Care

KVUE EPS (Earnings per Share)

EPS Growth (3Y CAGR): -58.19%
EPS Trend (3Y Correlation): -43.2%

KVUE Revenue

Revenue Growth (3Y CAGR): 0.55%
Revenue Trend (3Y Correlation): -10.9%

Description: KVUE Kenvue

Kenvue Inc. (NYSE: KVUE) is a global consumer-health company headquartered in Summit, New Jersey, operating across North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America. The firm was spun out of Johnson & Johnson in 2022 and now trades as a standalone public company.

The business is organized into three product-centric segments:

Self-Care: Over-the-counter (OTC) medicines and wellness items such as cough, cold, allergy, pain, digestive health, smoking-cessation and eye-care products. Core brands include Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORS™, Rhinocort, Calpol and Zyrtec.
Skin Health & Beauty: Personal-care and cosmetics ranging from facial and body moisturizers to hair and sun-care. Flagship names are Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine and OGX.
Essential Health: Oral-care, infant-care, women’s health, wound-care and related categories, anchored by Listerine, Johnson’s, Band-Aid, Stayfree, o.b., Carefree and Desitin.

In its most recent fiscal year (FY 2023), Kenvue reported net sales of roughly $15.9 billion, with the Self-Care segment contributing about 55 % of total revenue and delivering an adjusted EBITDA margin near 19 %. The Skin Health & Beauty segment grew at a 5-6 % compound annual growth rate (CAGR) over the past three years, driven by premium-price positioning and expanding e-commerce penetration.

Key macro-drivers for Kenvue include: (1) steady demand for OTC therapeutics, which the IQVIA OTC market size is projected to exceed $45 billion globally by 2027; (2) inflation-sensitive pricing dynamics, as higher input costs compress margins unless offset by brand-strength pricing power; and (3) shifts in consumer health behavior post-pandemic, with a measurable uptick in self-care spending that outpaces overall retail growth (≈3 % annual excess). These factors collectively shape the firm’s earnings outlook and valuation multiples relative to the broader Personal Care Products sub-industry.

For a deeper quantitative comparison of KVUE’s valuation metrics against peers, you may find ValueRay’s analytical tools useful.

KVUE Stock Overview

Market Cap in USD	29,343m
Sub-Industry	Personal Care Products
IPO / Inception	2023-05-04

KVUE Stock Ratings

Growth Rating	-53.4%
Fundamental	56.8%
Dividend Rating	70.8%
Return 12m vs S&P 500	-40.7%
Analyst Rating	3.42 of 5

KVUE Dividends

Dividend Yield 12m	5.42%
Yield on Cost 5y	3.33%
Annual Growth 5y	102.50%
Payout Consistency	100.0%
Payout Ratio	76.9%

KVUE Growth Ratios

Growth Correlation 3m	-95.6%
Growth Correlation 12m	-42.6%
Growth Correlation 5y	3.7%
CAGR 5y	-17.93%
CAGR/Max DD 3y (Calmar Ratio)	-0.41
CAGR/Mean DD 3y (Pain Ratio)	-0.96
Sharpe Ratio 12m	-1.11
Alpha	-39.33
Beta	0.673
Volatility	50.59%
Current Volume	23711.6k
Average Volume 20d	30873.3k
Stop Loss	14.6 (-3.9%)
Signal	0.04

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (1.42b TTM) > 0 and > 6% of Revenue (6% = 908.5m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -0.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -0.89% (prev -0.36%; Δ -0.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 2.09b > Net Income 1.42b (YES >=105%, WARN >=100%)

Net Debt (7.67b) to EBITDA (3.04b) ratio: 2.53 <= 3.0 (WARN <= 3.5)

Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.93b) change vs 12m ago 0.36% (target <= -2.0% for YES)

Gross Margin 57.99% (prev 57.51%; Δ 0.48pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 56.52% (prev 58.52%; Δ -2.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.30 (EBITDA TTM 3.04b / Interest Expense TTM 458.0m) >= 6 (WARN >= 3)

Altman Z'' 0.23

(A) -0.00 = (Total Current Assets 5.85b - Total Current Liabilities 5.99b) / Total Assets 27.13b

(B) -0.01 = Retained Earnings (Balance) -136.0m / Total Assets 27.13b

(D) -0.32 = Book Value of Equity -5.19b / Total Liabilities 16.40b

Total Rating: 0.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.79

1. Piotroski 4.50pt = -0.50

2. FCF Yield 4.41% = 2.21

3. FCF Margin 10.79% = 2.70

4. Debt/Equity 0.81 = 2.18

5. Debt/Ebitda 2.53 = -1.01

6. ROIC - WACC (= 2.43)% = 3.04

7. RoE 13.80% = 1.15

8. Rev. Trend -10.90% = -0.82

9. EPS Trend -43.17% = -2.16

What is the price of KVUE shares?

As of October 23, 2025, the stock is trading at USD 15.19 with a total of 23,711,627 shares traded.
Over the past week, the price has changed by -6.58%, over one month by -10.49%, over three months by -32.35% and over the past year by -31.27%.

Is Kenvue a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Kenvue is currently (October 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 56.79 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KVUE is around 14.95 USD . This means that KVUE is currently overvalued and has a potential downside of -1.58%.

Is KVUE a buy, sell or hold?

Kenvue has received a consensus analysts rating of 3.42. Therefor, it is recommend to hold KVUE.

Strong Buy: 3
Buy: 2
Hold: 14
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the KVUE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	20.6	35.8%
Analysts Target Price	20.6	35.8%
ValueRay Target Price	16.4	8%

Last update: 2025-10-20 03:56

KVUE Fundamental Data Overview

Market Cap USD = 29.34b (29.34b USD * 1.0 USD.USD)
P/E Trailing = 20.3867
P/E Forward = 14.2045
P/S = 1.938
P/B = 2.8133
P/EG = 0.7931
Beta = 0.673
Revenue TTM = 15.14b USD
EBIT TTM = 2.43b USD
EBITDA TTM = 3.04b USD
Long Term Debt = 7.06b USD (from longTermDebt, last quarter)
Short Term Debt = 1.59b USD (from shortTermDebt, last quarter)
Debt = 8.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.67b USD (from netDebt column, last quarter)
Enterprise Value = 37.02b USD (29.34b + Debt 8.74b - CCE 1.07b)
Interest Coverage Ratio = 5.30 (Ebit TTM 2.43b / Interest Expense TTM 458.0m)
FCF Yield = 4.41% (FCF TTM 1.63b / Enterprise Value 37.02b)
FCF Margin = 10.79% (FCF TTM 1.63b / Revenue TTM 15.14b)
Net Margin = 9.37% (Net Income TTM 1.42b / Revenue TTM 15.14b)
Gross Margin = 57.99% ((Revenue TTM 15.14b - Cost of Revenue TTM 6.36b) / Revenue TTM)
Gross Margin QoQ = 58.90% (prev 57.95%)
Tobins Q-Ratio = 1.36 (Enterprise Value 37.02b / Total Assets 27.13b)
Interest Expense / Debt = 1.22% (Interest Expense 107.0m / Debt 8.74b)
Taxrate = 28.57% (168.0m / 588.0m)
NOPAT = 1.73b (EBIT 2.43b * (1 - 28.57%))
Current Ratio = 0.98 (Total Current Assets 5.85b / Total Current Liabilities 5.99b)
Debt / Equity = 0.81 (Debt 8.74b / totalStockholderEquity, last quarter 10.73b)
Debt / EBITDA = 2.53 (Net Debt 7.67b / EBITDA 3.04b)
Debt / FCF = 4.70 (Net Debt 7.67b / FCF TTM 1.63b)
Total Stockholder Equity = 10.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.23% (Net Income 1.42b / Total Assets 27.13b)
RoE = 13.80% (Net Income TTM 1.42b / Total Stockholder Equity 10.27b)
RoCE = 14.00% (EBIT 2.43b / Capital Employed (Equity 10.27b + L.T.Debt 7.06b))
RoIC = 9.18% (NOPAT 1.73b / Invested Capital 18.88b)
WACC = 6.75% (E(29.34b)/V(38.09b) * Re(8.50%) + D(8.74b)/V(38.09b) * Rd(1.22%) * (1-Tc(0.29)))
Discount Rate = 8.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.31%
[DCF Debug] Terminal Value 72.53% ; FCFE base≈1.69b ; Y1≈1.34b ; Y5≈890.7m
Fair Price DCF = 7.97 (DCF Value 15.29b / Shares Outstanding 1.92b; 5y FCF grow -24.82% → 3.0% )
EPS Correlation: -43.17 | EPS CAGR: -58.19% | SUE: -4.0 | # QB: 0
Revenue Correlation: -10.90 | Revenue CAGR: 0.55% | SUE: -0.16 | # QB: 0

Additional Sources for KVUE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle